Table 1 Demographic and clinical data.

From: Investigation of the prognostic predictive value of serum lipid profiles in amyotrophic lateral sclerosis: roles of sex and hypermetabolism

  

All

Male patients

Female patients

 
 

n

78

38

40

 

Age (y)

78

71 [66, 75]

70 [64, 75]

73 [67, 75]

 

ALSFRS-R score

69

41.00 [36, 44]

38 [35, 43]

42 [39, 44]

 

ΔALSFRS-R

69

0.56 [0.27, 1.00]

0.56 [0.26, 1.00]

0.52 [0.31, 0.87]

 

BMI at the first visit (kg/m2)

78

21.7 [18.7, 24.1]

22.1 [20.0, 24.5]

20.8 [18.5, 23.4]

 

ΔBMI

74

0.19 [0.01, 0.33]

0.18 [0.01, 0.43]

0.20 [0.07, 0.31]

 

Bulbar type (yes)

 

26/78 (33%)

11/38 (29%)

15/40 (38%)

 

Hypermetabolism (yes)

 

25/53 (47%)

9/24 (38%)

16/29 (55%)

 

mREE/LSTM (kcal/kg)

53

37.1 [34.5, 41.2]

35.6 [34.0, 39.2]

38.7 [34.5, 42.6]

 

Statin use (yes)

 

21/78

7/38 (18%)

14/40 (35%)

 

%VC (%)

70

88 [78, 95]

90 [81, 99]

87 [72, 95]

 

Endpoint

 

41/78

22/38

19/40

 

Blood test for the first time

    

p*

HDL (mg/dL)

78

63 [50, 75]

60 [49, 71]

65 [57, 76]

0.175

High HDL

 

23

10/38 (26%)

13/40 (33%)

0.62

LDL (mg/dL)

78

115 [96, 139]

111 [80, 125]

129 [104, 143]

0.008

Low LDL

 

19

10/38 (26%)

9/40 (23%)

0.79

TG (mg/dL)

77

109 [74, 143]

120 [76, 164]

103 [73, 136]

0.51

Low TG

 

20

9/38 (24%)

11/39 (28%)

0.80

Interval between the onset and

     

blood test (months)

78

10 6,15

11 6,18

9.00 [6.00, 13]

 
  1. Data are presented as median [interquartile range]. Due to missing values, the number corresponding to each factor does not necessarily add up to the total number of 78. *P-value is based on Fisher's exact test or the Mann–Whitney U test.
  2. ALSFRS-R, Revised Amyotrophic Lateral Functional Rating Scale; BMI, body mass index; BMM index, BMI muscle metabolism index; mREE, measured resting energy expenditure; LSTM, lean soft tissue mass; VC, vital capacity; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglycerides.
  3. Significant values are in [bold].